Leadership Teams from Sanpower Group and BVCF Visited DiaCarta Headquarters | DiaCarta, Inc.

Leadership Teams from Sanpower Group and BVCF Visited DiaCarta Headquarters

by | May 16, 2016 | Blog

On a sunny day of May 10, 2016, executive teams from Sanpower Group/China Cord Blood Corporation and BVCF visited DiaCarta’s business headquarters and clinical services lab in Richmond California to learn more about the company’s business and clinical operations in the United States.

The representatives from Sanpower Group were led by Mr. Yuen Kam, Chairman of China Cord Blood Corporation (NY Stock Exchange CO). The BVCF team was led by Dr. Zhi Yang and Dr. Robert Li.

The visit was started by the tour of DiaCarta’s facility including its clinical services lab (the CLIA lab) where next-generation sequencing, quantitative PCR and other state-of-the-art genomic technologies are currently employed to develop advanced precision diagnostics products and services. The CLIA lab is also working diligently towards the GMP-level custom lentiviral CAR (Chimeric Antigen Receptor) construction and CAR-T cell manufacturing as part of the company’s new platform in precision CAR-T immunotherapy.

Following the tour, the executive teams attended the presentations led by Dr. Aiguo Zhang, Founder, President and CEO of DiaCarta and Dr. John Wu, the CEO of ProMab, DiaCarta’s partner in the precision immunotherapy platform. The visit was concluded after a stimulating discussion between the teams and other participants from DiaCarta, including Dr. Paul Okunieff (Co-Founder), Dr. Mike Powell (Chief Scientific Officer) and Dr. Mingyi Chen (Medical Director).

Sanpower visit_P1

Sanpower visit_p2

Sanpower visit_p3

About BVCF

Formally known as BioVeda China Fund, BVCF is a growth capital focused private equity fund specializing in China Life Sciences and Healthcare industry. The fund was the first US dollar fund that focused on life sciences and healthcare in China.  Headquartered in Shanghai, BVCF primarily focuses on equity investments in growth-stage companies in the field of Pharmaceuticals, Biotechnology, Traditional Chinese Medicine, Medical Devices, Healthcare Services, Industrial and Environmental Biotechnology.  In the past decade, BVCF invested in nearly 30 companies, has US$400 million under management; and offered co-investment opportunities with a combined value of over US$600 million. Its investments span across China and the U.S., covering a wide spectrum of highly promising subfields including healthcare services, innovative biologics, in-vitro diagnostics (molecular diagnostics), high value medical equipments and consumables, and medical big data and mobile medicine.

About Sanpower Group

Sanpower Group is a multi-national conglomerate whose core business engagements are within the technology and modern service industries. The Group offers a singular global platform for its five primary subsidiary investment sector-groups (Finance & Investment, Retail & Trading, Information Services, Medical & Health Care, and Real Estate) and owns a diverse portfolio of listed companies including Hiteker (600122.SH), Nanjing Cenbest (600682.SH), IDT International (0167.HK), Mecox Lane (NASDAQ:MCOX) and Jinpeng Yuankang (New Three Board 430606) as well as key privately held global enterprises such as Hisap, Funtalk Telecommunications, Hirealty, Guangzhou Jinpeng, China Newsweek, Lashou.com, Cnshangquan, House of Fraser (UK), Brookstone (US), and Natali (Israel). With both total assets and annual gross sales in excess of RMB 100 billion as well as controlling stakes in more than 100 subsidiaries, the Group is on the list of “China’s Top 500 Enterprises” for twelfth consecutive years (160th) and ranks 21st in “China’s Top 500 Private Enterprises” and 9th in “China’s Top 100 Private Service Enterprises” by All-China Federation of Industry and Commerce (ACFIC).

Lead Source

Confirmation of NGS for False-negative Variants Using XNA Technology

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.

XNA Molecular Clamps Help Identify False-positive T790M Mutation

Eighty five percent of the lung cancer patients are non-small cell lung cancer (NSCLC) patients. Among this population, patients with exon 19 deletion and L858R mutations respond well to the first (such as erlotinib and gefitinib) and second generation (such as afatinib and dacomitinib) of tyrosine kinase inhibitors (TKIs). However, all the respondents develop resistance after 9 to 14-month period and more than 50% of the resistance cases are due to the single point mutation at exon 20, T790M.

Colorectal Cancer: Early Screening Could Save Your Life

linkedinfacebooktwitterColorectal cancer (CRC), including colon and rectum cancer, is the third most common cancer in the world and the third in the US as well. American Cancer Society (ACS) estimates that there are 97,220 and 43,030 new cases in 2018 for colon and...

Detecting BRAF (V600E) Mutation in FFPE or Blood Samples

linkedin facebook twitter When mutated, oncogenes can convert normal cells to cancer cells. BRAF is one of the oncogenes that controls transduction of chemical signal from outside the cells to nucleus. As a member of the RAS/MAPK pathway, the BRAF gene product, the...

DiaCarta: Dedicated to the Science of Impact

linkedinfacebooktwitterMolecular Diagnostics has evolved over the years and the numerous benefits it has to offer has earned people’s attention irrespective of the expensive procedures it included. Quicker turnaround times, improved sensitivities, increased accuracy...

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!